Fenofibrate boosts metabolic hormone FGF21 in five-year diabetes trial, challenging previous assumptions

A five-year clinical trial reveals that fenofibrate significantly increases levels of the metabolic hormone FGF21, prompting questions about its role in ageing and cardiovascular health among people with type 2 diabetes. A five-year randomised trial has found that fenofibrate, a…















